BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School 2018: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
BioCentury | Jan 26, 2018
Company News

BIA intervenes on plausibility in patent law in Supreme Court case

...said the U.K. Supreme Court granted it permission to intervene in the court's review of Warner-Lambert...
...case involves a patent for the use of Lyrica pregabalin from Pfizer Inc. (NYSE:PFE), which Warner-Lambert...
...disorder and epilepsy. After Generics Ltd. and Actavis commenced claims to revoke Warner-Lambert's patent and Warner-Lambert...
BioCentury | May 12, 2014
Strategy

Build up to break up

...an aggregator, acquiring large companies and integrating them into its portfolio. In 2000, it acquired Warner-Lambert...
BioCentury | Nov 10, 2011
Targets & Mechanisms

Countering chemo-induced metastasis

...Bayer AG , Bristol-Myers Squibb Co. , British Biotech plc (now Vernalis plc ) and Warner-Lambert...
BioCentury | Apr 18, 2011
Strategy

Supercharging Astex

...the company acquired hairy cell leukemia drug Nipent pentostatin for undisclosed cash and equity from Warner-Lambert...
BioCentury | Jan 31, 2011
Strategy

Lysing what it sees

Since the approval of Dendreon Corp. 's Provenge finally validated the idea of cancer immunotherapy, one of the next big questions has been how this treatment modality would be incorporated into the portfolios of major...
BioCentury | Sep 2, 2010
Targets & Mechanisms

GSK's topoisomerase in the hole

...markets moxifloxacin, a fluoroquinolone antibiotic, under multiple brand names. Clinafloxacin was originally being developed by Warner-Lambert...
BioCentury | Mar 8, 2010
Strategy

OSI Chronicles

...Pfizer Inc. (NYSE:PFE), which enabled the pharma to satisfy FTC requirements for its merger with Warner-Lambert...
BioCentury | Feb 1, 2010
Regulation

Begging questions about REMS

...but they were generally unsuccessful in getting compliance to test for liver function," he said. Warner-Lambert...
BioCentury | Nov 10, 2008
Regulation

Narrowing down preemption

...'new information' up in the Vermont courts," Bradshaw said. He added that in another case, Warner-Lambert...
Items per page:
1 - 10 of 385
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School 2018: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
BioCentury | Jan 26, 2018
Company News

BIA intervenes on plausibility in patent law in Supreme Court case

...said the U.K. Supreme Court granted it permission to intervene in the court's review of Warner-Lambert...
...case involves a patent for the use of Lyrica pregabalin from Pfizer Inc. (NYSE:PFE), which Warner-Lambert...
...disorder and epilepsy. After Generics Ltd. and Actavis commenced claims to revoke Warner-Lambert's patent and Warner-Lambert...
BioCentury | May 12, 2014
Strategy

Build up to break up

...an aggregator, acquiring large companies and integrating them into its portfolio. In 2000, it acquired Warner-Lambert...
BioCentury | Nov 10, 2011
Targets & Mechanisms

Countering chemo-induced metastasis

...Bayer AG , Bristol-Myers Squibb Co. , British Biotech plc (now Vernalis plc ) and Warner-Lambert...
BioCentury | Apr 18, 2011
Strategy

Supercharging Astex

...the company acquired hairy cell leukemia drug Nipent pentostatin for undisclosed cash and equity from Warner-Lambert...
BioCentury | Jan 31, 2011
Strategy

Lysing what it sees

Since the approval of Dendreon Corp. 's Provenge finally validated the idea of cancer immunotherapy, one of the next big questions has been how this treatment modality would be incorporated into the portfolios of major...
BioCentury | Sep 2, 2010
Targets & Mechanisms

GSK's topoisomerase in the hole

...markets moxifloxacin, a fluoroquinolone antibiotic, under multiple brand names. Clinafloxacin was originally being developed by Warner-Lambert...
BioCentury | Mar 8, 2010
Strategy

OSI Chronicles

...Pfizer Inc. (NYSE:PFE), which enabled the pharma to satisfy FTC requirements for its merger with Warner-Lambert...
BioCentury | Feb 1, 2010
Regulation

Begging questions about REMS

...but they were generally unsuccessful in getting compliance to test for liver function," he said. Warner-Lambert...
BioCentury | Nov 10, 2008
Regulation

Narrowing down preemption

...'new information' up in the Vermont courts," Bradshaw said. He added that in another case, Warner-Lambert...
Items per page:
1 - 10 of 385